Background and study aims
Self-expandable metallic stents (SEMS) are now widely used even for patients with borderline resectable (BR)
pancreatic cancer (PC), as
neoadjuvant therapy has become common. Therefore, we conducted this study to evaluate safety of SEMS placement in the population including BR PC and to explore risk factors for recurrent biliary obstruction (RBO),
pancreatitis, and
cholecystitis. Patients and methods We retrospectively investigated consecutive patients with PC who received initial SEMS between January 2015 and March 2019. We compared time to RBO (TRBO), causes of RBO, and
stent-related adverse events (AEs) according to resectability status. Univariate and multivariate analyses were performed to explore risk factors for TRBO,
pancreatitis, and
cholecystitis. Results A total of 135 patients were included (BR 31 and unresectable [UR] 104).
Stent-related AEs occurred in 39 patients:
pancreatitis 14 (mild/moderate/severe 1/6/7),
cholecystitis 12, and non-occluding
cholangitis 13. TRBO, causes of RBO, and
stent-related AEs were not significantly different according to resectability status. Overall rate of RBO was higher in UR PC due to the longer follow-up period. Sharp common bile duct (CBD) angulation was an independent risk factor for short duration of TRBO. High pancreatic volume index and SEMS of high axial force were independent risk factors for
pancreatitis, whereas
tumor involvement to orifice of cystic duct was the only risk factor for
cholecystitis. Conclusions We demonstrated that SEMS can be safely deployed even in patients with BR PC. Sharp CBD angulation and high pancreatic volume index were identified as novel risk factors for RBO and
pancreatitis, respectively, after SEMS placement.